MedTrace Logo

Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy IDEAL Stage 2a

NCT07678489 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-01

No results posted yet for this study

Summary

Prospective single-arm IDEAL stage 2a feasibility study of urethra-preserving RARP in localized prostate cancer.

Conditions

  • Prostate Cancer (Localized), Urinary Incontinence (C61)

Interventions

PROCEDURE

ToP-RAP

\*\*ToP-RAP\*\* is a urethra-preserving modification of robot-assisted radical prostatectomy (RARP) for localized prostate cancer. Its distinguishing feature is preservation of the \*\*entire intraprostatic urethra with complete omission of urethral transection and the vesicourethral anastomosis\*\*. This separates it mechanistically from standard RARP, Retzius-sparing RARP, and the hood and sleeve techniques - all of which transect the urethra and reconstruct a vesicourethral anastomosis - and from urethra-sparing \*simple\* prostatectomy, which is a benign (BPH) enucleation rather than whole-gland cancer surgery. The whole prostatic gland is removed while only the intraprostatic urethra is retained, with anterolateral neurovascular-bundle preservation.

Sponsors & Collaborators

  • Clinic Bel Etage Dusseldorf, NRW, Germany

    collaborator UNKNOWN

  • Sami-Ramzi Leyh-Bannurah

    lead OTHER

Principal Investigators

  • Sami-Ramzi Leyh-Bannurah, Associate Professor · Martini Klinik am UKE GmbH, Hamburg-Eppendorf, Hamburg, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-30
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07678489 on ClinicalTrials.gov